NETTER-1 Overall survival
In the phase III NETTER-1 trial, patients with advanced, progressive neuroendocrine tumours (NETs) were randomised to LUTATHERA® (lutetium [177Lu] oxodotreotide) (every 8 weeks, four cycles) plus octreotide long-acting release (LAR) 30 mg or octreotide LAR 60 mg (of note, the 60 mg dose is not the licensed dose).1
In the primary analysis, the study showed a significantly longer progression-free survival (PFS) in the LUTATHERA arm.2 The final analysis showed a positive trend in overall survival (OS) (not statistically significant; median OS of 48.0 months [95% confidence interval (CI): 37.4–55.2] in the LUTATHERA arm vs 36.3 months [95% CI: 25.9–51.7] with high-dose octreotide LAR; p=0.30).
Please explore the available resources below on the final analysis of NETTER-1:
This leaflet summarises the final analysis of the NETTER-1 trial, including PFS, OS and safety data:
This slide deck summarises the NETTER-1 trial, including trial design, PFS analysis data, OS final analysis data and long-term safety data:
References
- Strosberg J, Kunz PL, Hendifar A, et al; NETTER-1 study group. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. 2020;47:2372–82.
- Lutathera® Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_en.pdf. (Accessed December 2023).
